An Open Label, Phase I Study to Evaluate the Impact of Severe Hepatic Impairment on the Pharmacokinetics and Safety of Vemurafenib in BRAF V600 Mutation Positive Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 15 Feb 2018
At a glance
- Drugs Vemurafenib (Primary)
- Indications Solid tumours
- Focus Pharmacokinetics
- Sponsors Roche
- 14 Dec 2017 Status changed from active, no longer recruiting to completed.
- 05 Jul 2017 Planned End Date changed from 1 Nov 2016 to 14 Jul 2017.
- 05 Jul 2017 Status changed from recruiting to active, no longer recruiting.